In an analysis of 240 patients with advanced MCC receiving avelumab in the context of the expanded access program of the JAVELIN trial, the PD-L1 inhibitor confirmed a manageable safety profile [170]. The gene discussed is CD274; the disease is Merkel cell skin cancer.